Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaMichèle Cavo, Antonio Palumbo, Lucia Pantani et al.|Blood|2012Cited by 310
Superior Complete Response Rate (CR) and Progression-Free Survival (PFS) with Bortezomib-Thalidomide-Dexamethasone (VTD) Versus Thalidomide-Dexamethasone (TD) As Consolidation Therapy After Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)Michèle Cavo, Michele Baccarani, Lucia Pantani et al.|Blood|2011Cited by 7
Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDMAnnamaria Brioli, Michèle Cavo, Letizia Canepa et al.|Blood|2014Cited by 3
Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple MyelomaMichèle Cavo, Mario Boccadoro, Mónica Galli et al.|Blood|2012Cited by 3
Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)Paola Tacchetti, Michèle Cavo, Carolina Terragna et al.|Blood|2011Cited by 1